Fibroblast growth factor 23 (FGF23) regulates phosphate and vitamin D homeostasis and rises as kidney function declines. Animal studies have demonstrated direct and indirect effects of FGF23 that may promote heart disease. Herein, we review the recent epidemiologic literature evaluating the relationship between FGF23 and cardiovascular disease.
INTRODUCTION
Fibroblast growth factor 23 (FGF23) is a 32-kDa hormone that regulates phosphate and vitamin D homeostasis by augmenting urinary phosphate excretion and limiting conversion of 25-hydroxyvitamin D to its active form, 1,25-dihydroxyvitamin D. Lowered 1,25-dihydroxyvitamin D subsequently reduces the absorption of phosphate in the gastrointestinal tract and promotes secondary hyperparathyroidism. Thus, FGF23 coordinates an integrated endocrine axis whose normal function maintains phosphate and vitamin D homeostasis in healthy individuals. In the setting of chronic kidney disease (CKD), adaptations in this axis frequently occur to maintain phosphate excretion despite its reduced renal filtration [1] .
Dysfunction of this phosphate/vitamin D axis was initially highlighted as a risk factor for accelerated cardiovascular disease in patients on dialysis. This was supported by observations that higher serum phosphate was associated with increased mortality risk, whereas restoration of vitamin D activity with the therapeutic administration of active analogues was associated with lower risk [2, 3] . Interest grew further with the discovery of a relationship between higher FGF23 and all-cause mortality in patients with end-stage renal disease on dialysis, with CKD stages 2À4 and in the general population [4] [5] [6] [7] . Cross-sectionally, FGF23 associated with cardiac remodeling suggesting that the increased mortality risk could be attributable to cardiovascular effects [8, 9] .
Consistent with these observations, elegant experiments in animal models have documented direct effects of FGF23 to promote hypertrophy, contractility and arrhythmic potential of the myocardium [10] [11] [12] . Additional studies have found indirect adverse cardiac effects of FGF23, such as activation of the renin-angiotensin system and promotion of sodium reabsorption in the distal tubule of the kidney [13] [14] [15] . As a result of this initial body of epidemiologic and basic research, a compelling hypothesis emerged in which elevation of FGF23, although necessary to control phosphate and vitamin D homeostasis, may also contribute to the development of cardiovascular disease.
Bolstered by these exciting findings in controlled animal experiments, there has been an expanding body of epidemiologic literature evaluating FGF23 as a risk factor for clinical cardiovascular disease events. This review will focus on recent insights from such epidemiologic studies, with an emphasis on studies published in the last 12-18 months. The observational studies discussed here critically translate basic findings to diverse human populations and ultimately pave the way for interventional studies targeting FGF23 and the phosphate/vitamin D axis.
EPIDEMIOLOGY OF FIBROBLAST GROWTH FACTOR 23 AND CARDIOVASCULAR DISEASE
Higher FGF23 was initially described as a risk factor for clinical cardiovascular events in relatively small studies of adults with established coronary artery disease or moderate to advanced CKD [6, 7, 16] . Similar results were subsequently reported in two studies of older adults in the general population [17, 18] . Recently, there have been new reports from a variety of cohort studies in the general population [19,20 && . Figure 1 provides a qualitative summary and overview of populations and outcomes assessed in prospective studies that will be discussed in this review. These studies largely support a relationship between higher FGF23 and cardiovascular disease that is independent of kidney function, and, collectively, they address several key questions that advance the field.
Is there a dose-response relationship between fibroblast growth factor 23 and cardiovascular events?
In most studies, the relationships between higher FGF23 levels and cardiovascular disease are generally graded [6, 17, 20 && ,23
For instance, in the Chronic Renal Insufficiency Cohort (CRIC) Study, we found that the relative risk of atherosclerotic events and cardiovascular events increased by 24% and 45%, respectively, with each two-fold increase in FG23 after multivariable adjustment including adjustment for kidney function [26 & ]. This finding was remarkably similar to effect estimates observed within the CKD subgroup in the Cardiovascular Health Study (CHS) [17] . We examined relative, or multiplicative, differences in FGF23 because of the exponential increase of FGF23 as kidney function declines [32] ; however, some studies in the general population have looked at the risk associated with absolute, or additive, differences in FGF23 [18,20 && ,21 && ]. These modeling differences make it difficult to directly compare shapes of associations across different populations. Despite the differences, some studies in the general population have also found a gradient of risk with a relatively linear association between higher absolute FGF23 levels and risk of cardiovascular disease [18,20 && ]. They reported a threshold level of FGF23, with a graded relationship between higher intact FGF23 and risk of incident coronary heart disease, heart failure or cardiovascular mortality at levels above, but not below, 40 pg/ml. In other general population studies, confidence intervals were often wide in these lower ranges [18,20 && ], and, therefore, the power available in the ARIC Study
KEY POINTS
Higher levels of FGF23 associate independently with a greater risk of incident cardiovascular disease in prospective studies, including ischemic heart disease, stroke, congestive heart failure and atrial fibrillation.
The risk associated with higher FGF23 may be greater in patients with kidney disease. In this setting levels are generally higher and may be associated with other adverse factors such as deficiency of the FGF23 coreceptor, klotho and higher phosphate.
Across studies, higher FGF23 is more consistently associated with an increased risk of heart failure compared with atherosclerotic event types.
Interventional studies targeting dietary phosphate or phosphate absorption are needed to determine whether FGF23 can be lowered and whether this translates to prevention of cardiovascular disease.
may have allowed detection of this flat portion of the curve. Alternatively, differences in modeling decisions, such as lack of adjustment for estimated glomerular filtration rate (eGFR) variation within the normal range (i.e. eGFR ! 60 ml/min/1.73 m 2 ) or use of intact as opposed to C-terminal assays, may account for the slightly different shape of the association in this study.
How does fibroblast growth factor 23 relate to different cardiovascular disease event subtypes?
Although many studies have found that higher FGF23 is independently associated with atherosclerotic endpoints, such as myocardial infarction, peripheral vascular disease and stroke [7, 16, 17 ]. This difference could be due to ascertainment of heart failure events largely by billing codes in this study as opposed to medical record adjudication in many of the other reports [6, 17, 20 
In the last year, the role of FGF23 as a risk factor for atrial fibrillation has been investigated in three of the large general population cohorts. In each study atrial fibrillation was ascertained through billing claims and study-related electrocardiograms. Higher How do relationships between fibroblast growth factor 23 and clinical cardiovascular disease align with subclinical cardiovascular disease outcomes?
The stronger and consistent relationships between FGF23, heart failure and atrial fibrillation are particularly intriguing in light of numerous crosssectional studies linking higher FGF23 with abnormal left ventricular geometry, including higher left ventricular mass, higher left ventricular mass-tovolume ratio and greater risk of hypertrophy and remodeling [ ]. Although children are less likely to have preexisting heart disease that would confound these relationships, FGF23 was correlated with many other adverse metabolic risk factors such as insulin resistance, obesity and inflammation.
The observed differences in left ventricular geometry may be direct pathologic mechanisms leading to heart failure and atrial fibrillation and are supported by induction of these changes by higher FGF23 in experimental animal models [10, 11, 15] . To determine if changes in ventricular geometry may account for the relationships between FGF23 and cardiovascular disease, heart failure, or atrial fibrillation, several of the studies have additionally adjusted for measures of left ventricular mass or left atrial diameter [17] [18] [19] 24 & ,26 & ]. In each case, adjustment for ventricular geometry did not fully attenuate the relationship of FGF23 with clinical events. However, these mediation analyses should be interpreted cautiously for a number of reasons: first, generally FGF23 and left ventricular geometry have been measured concurrently and therefore the temporal sequence of events may be violated; second, left ventricular geometry is measured imprecisely and at one timepoint, therefore, may not fully capture cumulative effects on the myocardium; and third, other biases inherent to mediation analysis methodology may limit inferences [36, 37] .
In contrast to relatively consistent associations between FGF23 and cardiac geometry, the associations between FGF23 and subclinical atherosclerotic disease are more variable. In CRIC, we found no independent association between FGF23 and presence or severity of coronary artery calcification [38] , although associations have been reported in other large studies [20 && ]. The associations between FGF23 and other measures of atherosclerosis or vascular elasticity, such as ankle brachial index, carotid intima-media thickness and arterial elasticity, have been mixed with many [20 && ,31,39], but not all [40, 41] , studies showing no association. Some investigators have reported that FGF23 expression can be induced in atherosclerotic plaques; thus, some of these associations may be a result of this process [42] .
Are the cardiovascular risks associated with fibroblast growth factor 23 stronger in patients with preexisting chronic kidney disease?
In the CRIC study of patients with CKD and median levels of C-terminal FGF23 of 145 RU/ml (IQR 96 to 239 RU/ml), the highest quartile compared with the lowest was independently associated with a higher risk of cardiovascular events, including a 1.8-fold increased risk of atherosclerotic events, such as myocardial infarction, stroke and peripheral arterial disease events, and a three-fold higher risk of congestive heart failure [26 & ]. In contrast, most estimates of the association between FGF23 and cardiovascular disease in the general adult population have been more modest with an approximately 1.3-1.7-fold higher ]. As discussed above, differences in modeling strategies and follow-up time make it difficult to directly compare these effects across studies. Consistent with potentially larger associations observed in the CRIC Study, several studies have found stronger relationships between FGF23 and both subclinical and clinical cardiovascular outcomes in patients with CKD compared with those with normal kidney function within their study populations [17,18, 38, 43, 44] . Perhaps, most interestingly, FGF23 appears to be most tightly linked to subtypes of cardiovascular disease that are particularly related to CKD, such as heart failure, atrial fibrillation and intracranial hemorrhage [45] [46] [47] [48] [49] . The overlap in these disease patterns could indicate that FGF23 is a major mediator of cardiovascular disease in patients with CKD, or that FGF23 levels are indicative of components of kidney dysfunction that are at least partially independent of GFR, such as tubular functions [18, 32] . Where reported, adjustment for FGF23 may partially, but does not fully, attenuate the association between CKD and subclinical or clinical cardiovascular disease [24 & ,50]; however, the formerly reviewed caveats of mediation studies also apply here [36, 37] .
TRANSLATING EPIDEMIOLOGIC FINDINGS AND THE ROLE OF FIBROBLAST GROWTH FACTOR 23 IN CARDIOVASCULAR DISEASE PREVENTION
The relatively consistent relationships observed between FGF23 and cardiovascular disease have several potential applications and implications that could be harnessed for patient care and prevention.
Fibroblast growth factor 23 as a biomarker of cardiovascular disease
One potential application of the observed epidemiologic associations between higher FGF23 and cardiovascular disease is its use as a predictive biomarker. Independent effect sizes may not be large enough to add meaningfully to disease prediction models Fibroblast growth factor 23 as a correlate of a cause of cardiovascular disease A third possibility is that FGF23 is correlated with other causes of cardiovascular disease, most notably other mineral metabolites that may also have adverse cardiovascular effects [6, 38, 44, [51] [52] [53] [54] . In particular, higher serum phosphate is associated with increased risk of cardiovascular disease and promotes vascular calcification and dysfunction experimentally [38, 52, [54] [55] [56] , whereas deficiency of the FGF23 coreceptor, klotho, may also directly induce vascular calcification and cardiac hypertrophy [44, 57] . Although associations between FGF23 and cardiovascular disease are almost uniformly independent of other measurable mineral metabolites, such as phosphate [16, 19, 20 
25,26
& ,28], it is important to recognize that many of these exhibit substantial biological variability, making them difficult to fully quantify and account for in analyses. In fact, several features of FGF23 measurement may make it the optimal biomarker for global dysfunction of the phosphate/vitamin D axis, including a favorable half-life with lower biological variability [27 & ,58] , easy measurement in the circulation that is the biologically relevant site of action and a broad biological range allowing greater between individual discrimination. It is not known how much these measurement properties contribute to the 'rank order' of associations observed between mineral metabolites and cardiovascular disease, but ultimately this distinction may not be critical if treatment strategies focus on normalizing this homeostatic axis globally.
MOVING 'UPSTREAM'
Recent preclinical animal studies that attempt to interrupt endocrine loops involving FGF23 dramatically raise serum phosphate and offer a warning for approaches to FGF23-lowering therapies [59] . FGF23 has a critical role in the homeostatic control of phosphate and vitamin D, each of which may have adverse effects if uncontrolled. The current body of evidence linking FGF23 with cardiovascular disease is compelling and warrants action, but more work is needed to understand how to modify FGF23 and, hence, the full phosphate/ vitamin D axis using targets that are 'upstream' of FGF23. Upstream targets, such as changes in dietary phosphate as well as existing or novel agents that limit phosphate absorption, hold the potential to interrupt the root causes of phosphate/vitamin D axis dysfunction and, therefore, could lower FGF23 without adverse effects on phosphate or other mineral metabolites (Fig. 2) [60] [61] [62] [63] [64] . Few studies are available evaluating the relationship between phosphate intake and cardiovascular disease [65] [66] [67] [68] [69] , and these efforts face enormous challenges including inaccurate dietary reporting, limitations of nutrition databases in terms of phosphate content and inaccuracies in 24-h urine collections [70] [71] [72] . However, cross-cultural comparisons suggest that a reduction in dietary phosphate can be achieved with potentially large consequences for regulatory hormones, such as FGF23 [73 & ]. Despite the challenges, more work is needed in this area.
CONCLUSION
Recent studies affirm the strong relationship between higher FGF23 and risk of cardiovascular events that is independent of kidney function and is observable among those without preexisting heart disease, in which FGF23 most clearly precedes disease development. It is currently not definitively known whether variation in FGF23 in the low-normal range, or only in the moderate-to-high range, is associated with risk of cardiovascular disease. Clarifying this at-risk range will be critical to identifying groups in which therapies to reduce FGF23 should be targeted. To date, most evidence has supported a stronger relationship between FGF23 and heart failure than atherosclerotic event subtypes, which may be consistent with its suggested roles in promoting left ventricular hypertrophy, sodium retention and renin-angiotensin system activation and modulating cardiac contractility. Ultimately, interventional trials aimed at the root cause of FGF23 elevation, such as excess dietary phosphate exposure, are required to understand whether FGF23 and the associated dysfunction of the phosphate/vitamin D axis is a modifiable cause of cardiovascular disease.
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